Fig. 2. Distribution of major ECM components in the normal artery wall and different stages of atherosclerosis.

Fig. 2

Distribution of major ECM components in the normal artery wall and different stages of atherosclerosis. Composition of ECM varies in different layers of the artery wall and at different stages of atherosclerosis. (a) Collagen I and decorin in the adventitia, along with collagens I and III, elastic fibers, and versican in the medial layer make up the majority of ECM in normal arterial walls. (b) Diffuse intimal thickening (DIT) is a thick layer of smooth muscle cells (SMCs) and proteoglycans (PGs) present in atherosclerosis-prone arteries beginning from birth. Biglycan, decorin, and versican secreted mainly by SMCs are the primary PGs in DIT, where biglycan and decorin are located in the deep intima and versican mainly in the superficial intima. (c) ApoB-containing lipoproteins that enter from the plasma via transcytosis through the endothelium are retained in the deep intima in early atherosclerosis due to a charge-charge interaction between apoB and glycosaminoglycan side chains of biglycan and decorin in the deep intima. (d) Trapped lipoproteins are modified, aggregated, and taken up by surrounding SMCs and macrophages to make foam cells (macrophages are omitted to emphasize the role of the ECM). Perlecan in mouse atheromas also binds lipoproteins but does not participate in this retention in humans. (e) Apoptosis/necrosis of foam cells leads to formation of a necrotic core in advanced atherosclerotic plaques, with versican being prominent at the edge. (f) Stable plaques are defined by the presence of a thick fibrous cap lying between the necrotic core and the luminal surface of the plaque. The fibrous caps consist of more differentiated SMCs and are enriched in versican, biglycan, and collagen type I, with lesser amounts of decorin and hyaluronan. (g) Unstable plaques with little or no fibrous cap show an intense staining for hyaluronan, versican, and collagen type III at the site of erosion and weak staining for biglycan and decorin

From: Smooth Muscle Cell-Proteoglycan-Lipoprotein Interactions as Drivers of Atherosclerosis

Cover of Prevention and Treatment of Atherosclerosis
Prevention and Treatment of Atherosclerosis: Improving State-of-the-Art Management and Search for Novel Targets [Internet].
von Eckardstein A, Binder CJ, editors.
Cham (CH): Springer; 2022.
Copyright 2020, The Author(s)

Open Access This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence and indicate if changes were made.

The images or other third party material in this chapter are included in the chapter's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the chapter's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.